Scholar Rock heads into the back half of 2026 with an unusual tension: short interest is quietly climbing toward its highest level of the year, yet the Street remains uniformly bullish and an activist investor holds a meaningful stake on the register.
Short sellers have been building positions steadily since late July. Short interest now covers nearly 18% of the free float — up roughly 3% over the past month — after edging back from a brief mid-week spike to 18.6 million shares. That is a genuinely elevated level for a clinical-stage biotech, and it has been grinding higher since early August. The lending market, however, tells a less alarming story for bears. Availability is still comfortable at around 342% — meaning there are more than three shares available to borrow for every one already lent out — and the 52-week minimum availability never fell below 171%. Cost to borrow is minimal at just 0.51%, barely budged from recent weeks. The borrow market is easy; shorts are not under any squeeze pressure. The ORTEX short score of 72.3 places SRRK among the more closely watched names on the platform, but that score has been broadly stable over the past two weeks rather than accelerating.
Options traders are not adding much drama. The put/call ratio of 0.51 is almost exactly in line with the 20-day average, with a z-score near zero. That is a neutral read — no unusual demand for downside protection, no speculative call-buying surge. The next earnings event is not until November 11, so there is no immediate binary catalyst drawing options attention right now.
The Street disagrees with the bears firmly. Every recent analyst action has been constructive. JP Morgan raised its target to $63 from $56 in mid-August following the last earnings print, when the stock gained more than 10% in a single session. Citi lifted its target to $60. Wedbush and HC Wainwright both reiterate Outperform and Buy ratings. The consensus mean target of $60.75 implies roughly 10% upside from the current price near $55, a modest but real premium. The bull case centres on apitegromab's potential approval for spinal muscular atrophy — a rare-disease niche where commercial success could transform the company's economics. The bear case is the standard pre-revenue biotech risk: no approved product, no meaningful revenue, and an f-score of 2 reflecting weak fundamental quality. Forward EPS revisions rank in the 93rd percentile, which is striking for a loss-making company, but reflects analysts pricing in a commercialisation scenario rather than current earnings power.
The ownership picture adds one genuinely newsworthy element. Srinivas Akkaraju filed a Schedule 13D — an activist designation — in October 2025, disclosing a 7.2% stake of around 7 million shares. A 13D filing signals potential engagement rather than passive ownership, and Akkaraju's presence alongside FMR (14.8% per the latest institutional data), BlackRock (7.8%), and T. Rowe Price (5.6%) gives the register a quality tilt. Invus Public Equities, meanwhile, trimmed from 11.4% to 8.0% in a filing last month, and Redmile Group cut its position roughly in half to 3.6%. Insider activity over the past 90 days has been light sell-side flow — a handful of directors selling small amounts under pre-arranged 10b5-1 plans in July, totalling around $4 million net. Planned sales of this size carry little signal.
The setup to watch into November is whether short interest continues to build as the apitegromab approval timeline comes into sharper focus, or whether the bullish analyst consensus and activist presence attract enough new buying to work against the short position.
See the live data behind this article on ORTEX.
Open SRRK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
